Kineret halts organ damage in inflammatory genetic disorder

A new study shows that Kineret (anakinra), a drug developed by US biotech giant Amgen (Nasdaq: AMGN) approved in the USA in 2001 for the treatment of rheumatoid arthritis, is effective in stopping the progression of organ damage in people with neonatal-onset multisystem inflammatory disease (NOMID).

This rare and debilitating genetic disorder causes persistent inflammation and ongoing tissue damage. The research was performed by scientists at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health.

At higher doses can control damage that leads to vision and hearing loss